A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Medical Affairs Project Associate Specialist New Grad Trainee

Program ManagementPosted on Nov 9
Full-timeZug, SwitzerlandNo salary listed

About the Job

Requirements

  • Availability for a minimum of 9 months; 12 months is strongly preferred.
  • A completed bachelor's degree is required.
  • Strong logical and analytical thinking, with the ability to navigate complexity and structure ambiguous problems.
  • Ability to read, interpret and critically summarize scientific and clinical literature.
  • Awareness of, or willingness to learn, the compliance principles that govern Medical Affairs.
  • Advanced PowerPoint and Excel skills, and confidence using Microsoft Copilot and AI-enabled productivity tools.
  • Ability to take ownership of high-quality outputs and handle confidential information with discretion.
  • Strong written and verbal communication skills in English.
  • Flexibility to work 2–3 days per week in the Zug office; occasional travel is possible, mainly within the EU.
  • Ability to work collaboratively in a fast-moving, cross-functional and international environment.

Responsibilities

  • Support the International Medical Strategy & Operations team in planning, tracking and reporting on International Medical TTR strategic priorities and operating-model deliverables across international markets.
  • Prepare management materials, including leadership updates, pre-reads, meeting materials and executive presentations, translating complex information into clear, decision-ready outputs.
  • Support medical planning and budget cycles by consolidating regional and country inputs, tracking spend against plan and preparing summaries in partnership with Finance.
  • Contribute to evidence generation portfolio management by maintaining study trackers, including investigator-initiated studies and research collaborations, and preparing status, milestone and timeline overviews with partners.
  • Support scientific engagement and medical education activities, including the speaker engagement process and congress planning; activities are scientific and non-promotional.
  • Support the TOP 41 Centers of Excellence program through engagement mapping and project deliverables, with potential ownership depending on experience and interest.
  • Support field medical excellence initiatives, including field medical key performance indicators, dashboards, the quarterly medical insights process and training rollout.
  • Contribute to patient experience work, including patient advocacy and engagement and patient support programs.
  • Support cross-functional planning, governance meetings and operational follow-up to gain insight into the regional medical leadership agenda.
  • Depending on experience and interest, support projects involving artificial intelligence-enabled tools, customer relationship management and insights platforms, and other emerging medical priorities.

Desired Qualifications

  • A master's degree is a plus.
  • An academic background in life sciences, medicine, pharmacy, biomedical sciences, public health or another analytical discipline is preferred.
  • Interest in Medical Affairs, cardiology or rare diseases is valued.
  • Additional languages are a plus.
  • Twelve months of availability is strongly preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs